NasdaqCM - Nasdaq Real Time Price USD

Sunshine Biopharma, Inc. (SBFMW)

0.1177 +0.0340 (+40.62%)
As of 2:47 PM EDT. Market Open.
Loading Chart for SBFMW
DELL
  • Previous Close 0.0837
  • Open 0.0840
  • Bid --
  • Ask --
  • Day's Range 0.0840 - 0.1177
  • 52 Week Range 0.0840 - 0.1177
  • Volume 422
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2140
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

sunshinebiopharma.com

44

Full Time Employees

--

Fiscal Year Ends

Recent News: SBFMW

Compare To: SBFMW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SBFMW

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -15.29%

  • Return on Assets (ttm)

    -9.14%

  • Return on Equity (ttm)

    -18.48%

  • Revenue (ttm)

    26.74M

  • Net Income Avi to Common (ttm)

    -4.09M

  • Diluted EPS (ttm)

    -2.2140

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.43M

  • Total Debt/Equity (mrq)

    2.47%

  • Levered Free Cash Flow (ttm)

    -10.05M

Research Analysis: SBFMW

Company Insights: SBFMW

Research Reports: SBFMW

People Also Watch